Related Experiment Video
Updated: Jan 29, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Cardiovascular magnetic resonance T2* mapping for structural alterations in hypertrophic cardiomyopathy
Mareike Gastl1,2,3, Alexander Gotschy1,2, Jochen von Spiczak4
1Department of Cardiology, University Heart Center, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland.
Insights
Cardiovascular Magnetic Resonance (CMR) T2* mapping reveals lower T2* values in hypertrophic cardiomyopathy (HCM) patients, particularly those with myocardial fibrosis. This technique may help identify higher-risk HCM patients.
Area of Science:
- Cardiology
- Medical Imaging
- Biophysics
Background:
- Hypertrophic cardiomyopathy (HCM) presents with diverse morphology and prognosis.
- Myocardial fibrosis, linked to left ventricular mass (LVM) and ischemia mismatch, worsens HCM prognosis.
- Cardiovascular Magnetic Resonance (CMR) T2* mapping can detect ischemia and fibrosis.
Purpose of the Study:
- To evaluate the utility of CMR T2* mapping in characterizing structural changes in HCM patients.
- To compare T2* values between HCM patients and controls.
- To assess T2* values in HCM patients with and without myocardial fibrosis.
Main Methods:
- CMR T2* mapping was performed on 103 HCM patients and 20 controls using a 1.5T MR system.
- T2* values were acquired from a single midventricular short axis slice.
- Late gadolinium enhancement (LGE) was also performed, and T2* values were compared across groups.
Main Results:
- HCM patients exhibited significantly lower T2* values than controls (26.2 ± 4.6 ms vs. 31.3 ± 4.3 ms, p < 0.001).
- HCM patients with myocardial fibrosis showed reduced T2* values compared to those without fibrosis (25.2 ± 4.0 ms vs. 28.7 ± 5.3 ms, p = 0.003).
- A regression model incorporating maximum wall thickness, LVM, and T2* values achieved 80% accuracy in diagnosing HCM with or without fibrosis.
Conclusions:
- Parametric mapping revealed lower T2* values in HCM patients, especially those with myocardial fibrosis.
- T2* mapping may provide valuable information for identifying higher-risk HCM patient subgroups.
- These findings suggest T2* mapping's potential role in risk stratification for HCM.
Purpose:
Hypertrophic cardiomyopathy (HCM) is characterized by a heterogeneous morphology and variable prognosis. A mismatch between left ventricular mass (LVM) and microvascular circulation with corresponding relative ischemia has been implicated to cause myocardial replacement fibrosis that deteriorates prognosis. Besides parametric T1 mapping, Cardiovascular Magnetic Resonance (CMR) T2* mapping is able to identify ischemia as well as fibrosis in cardiac and extracardiac diseases. Therefore, we aimed to investigate the value of T2* mapping to characterize structural alterations in patients with HCM.
Methods:
CMR was performed on a 1.5 T MR imaging system (Achieva, Philips, Best, Netherlands) using a 5-channel coil in patients with HCM (n = 103, 50.6 ± 16.4 years) and in age- and gender-matched controls (n = 20, 44.8 ± 16.9 years). T2* mapping (1 midventricular short axis slice) was acquired in addition to late gadolinium enhancement (LGE). T2* values were compared between patients with HCM and controls as well as between HCM patients with- and without fibrosis.
Results:
HCM patients showed significantly decreased T2* values compared to controls (26.2 ± 4.6 vs. 31.3 ± 4.3 ms, p < 0.001). Especially patients with myocardial fibrosis presented with decreased T2* values in comparison to those without fibrosis (25.2 ± 4.0 vs. 28.7 ± 5.3 ms, p = 0.003). A regression model including maximum wall thickness, LVM and T2* values provided good overall diagnostic accuracy of 80% to diagnose HCM with and without fibrosis.
Conclusion:
In this study, parametric mapping identified lower T2* values in HCM patients compared to controls, especially in a sub-group of patients with myocardial fibrosis. As myocardial fibrosis has been suggested to influence prognosis of patients with HCM, T2* mapping may add information for identifying a higher risk sub-group of HCM patients.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Magnetic Resonance Imaging
Resonance and Hybrid Structures
Resonance Structures and Resonance Hybrids
The Lewis structure of a nitrite anion (NO2−) may actually be drawn in two different ways, distinguished by the locations of the N–O and N=O bonds.
Cardiomyopathy II: Dilated Cardiomyopathy
Atomic Nuclei: Magnetic Resonance
Resonance

